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INTRODUCTION
Actinic keratoses (AK) are commonly located on UV-damaged skin sites and present as erythematous macules, keratotic patches or plaques. [1] They are regarded as early in-situ squamous cell carcinoma (SCC) and the risk of a single AK lesion to progress into an invasive SCC ranges between 0.025 to 16% per year. [2, 3] Due to changed leisure activities and an ongoing demographic change in industrial countries an increasing prevalence of AKs can be observed. Predominantly elderly male patients and people with fair skin types are affected by field cancerisation. [4] In these sundamaged skin regions, subclinical and non-visible AK lesions are present adjacent to clinical apparent AKs. [5] A recent study reveals that already early AK lesions can progress into invasive SCC. [6] Another study showed that thin AKs show the same severity of dysplasia and consequently clinical thickness cannot predict aggressiveness of AKs. [7] Hence, it is not possible to predict if and which lesion will become invasive. Therefore, it is mandatory to monitor and treat the whole field of actinic damage.
However, established clinical classification schemes are based on lesion counts assessing the overall thickness of single AKs. [8] To redress these lesion-directed classifications recently a new field-directed assessment tool to evaluate AK severity on the head has been suggested. [9] As AKs are considered as chronic disease, the "actinic keratosis area and severity index" (AKASI) has been developed on the basis of other chronic disease monitoring tools such as the psoriasis area and severity index (PASI). To calculate AKASI, the head is divided into 4 regions (scalp, face, right/left cheek, chin, nose and ear) and each region is estimated for the affected area by AKs.
AK lesions are evaluated due to characteristic clinical signs such as erythema, thickness and distribution. 
MATERIALS AND METHODS

Study population
This retrospective study was performed at the Skin Cancer Centre of the RuhrUniversity Bochum (Bochum, Germany). The study was conducted according to the 
Data assessment
AKASI is routinely evaluated in all patients with AKs on the head to monitor disease severity. These assessments of the study population were performed by two investigators (TG, LS). To determine AKASI, the head is divided into four regions 
Photodynamic therapy
Field-directed PDT was performed with BF-200 ALA (Ameluz®, Biofrontera, Leverkusen, Germany) as photosensitizer and BF-RhodoLED lamp (narrow emission spectrum of 635nm ± 9nm) as light source. Prior to exposure, the skin was degreased and crusts or hyperkeratoses of AK lesions were thoroughly removed by gentle curettage. Afterwards, ALA gel was applied to the treatment field and covered with an occlusive, light protecting dressing (plastic foil (e.g. 3M Tegaderm™) and aluminium foil). After an incubation time of approximately 3 hours, the occlusion was removed and topical residuals were wiped off. Subsequently, the treatment field was illuminated for 10 minutes at a distance of 5-8cm from the skin surface, resulting in a total light dose of 37J/cm². If required, the patients were allowed to cool the skin with cool packs after intervention.
Statistical analysis
Data analysis was performed using the statistical package MedCalc software version Overall, 32 (97.0 %) patients showed a reduction and 1 (3.0%) patient an increase of AKASI at the follow-up visit compared to the baseline visit. The median (range) absolute difference was 2.6 (-1.6-5.4) and relative 73.7% (-34.8-100.0%). The
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Wilcoxon test showed highly significant differences (P < 0.0001) between both visits. (Fig 1a) . 14 (42.4%) patients showed an AKASI 100 (complete clearance), 16 (48.5%)
an AKASI 75 and 24 (72.7%) an AKASI 50, respectively. Subgroup analysis of the 32 patients with AKASI reduction offered a median (range) value of 75.3% (13.6-100.0%).
Subgroup analysis of patients with a positive history of at least more than one intervention and treatment naïve patients showed a median AKASI difference of 61.1%
(-34.8-100.0%) and 100.0% (13.6-100.0%), respectively (Fig 2) . The Mann-Whitney U test showed significant differences between the AKASI changes in these two groups (P = 0.0302). (Fig 3) Analysis of modified AKASI (only areas which were treated was summed up) show a median (range) reduction of 80.8% (-8.7-100.0%). The Wilcoxon test presented highly significant differences (P < 0.0001) between both visits (Fig 1b) . 16 (48.5%) patients
showed an AKASI 100 (complete clearance), 19 (57.6%) an AKASI 75 and 25 (75.8%)
an AKASI 50, respectively.
DISCUSSION
Current clinical classification systems for AKs are based on the evaluation of single lesions and mainly restricted to the clinical criteria thickness of individual lesions. [13] As it has been demonstrated that neither thickness of AK lesions predict its aggressiveness nor the clinical appearance correlate with the underlying histologic grading, a field-directed monitoring tool is highly demanded. [7, 14] The new quantitative assessment tool AKASI provides the possibility to compare evaluated discrete AKs and areas of field cancerisation on the head. This is the first study to Efficacy endpoints for AK therapy studies are usually defined as "patient complete clearance rate" (PCCR) or as "lesion complete clearance rate" (LCCR) but no graduated response reflecting area of disease has been reported to date. PCCR can be compared with an AKASI improvement of 100% (AKASI 100). The study showed an AKASI 100 in 42.4% of patients, which reveals a slightly less effective outcome compared to three randomized controlled trials (RCT) conducted with equivalent requirements concerning photosensitizer, narrow band light source and PDT protocol.
These trials showed PCCR of 78% [16] , 53% [17] and 62% [18] after one PDT after 12
weeks of follow-up. This difference can be based on the fact that the PCCR just evaluates AK lesions within the treated field and not the entire head. In contrast, the standard AKASI takes all lesions of the whole head into account. Moreover, an AKASI 100 can only be achieved in patients who presented AKASI sub scores solely in regions of the head which were undergoing an intervention. To overcome this problem, only sub scores of regions which had been treated were summed up to calculate a "modified" AKASI. The modified AKASI 100 of the treatment area was 48.5%. It still shows lower complete clearance rates in this analysis, which might be due to different factors: non RCT, done in daily routine, AKASI differs in general from PCCR, more clinical characteristic signs of AK for assessing AKASI might be more sensitive for evaluating minor AK residuals. It is questionable if it will be necessary to compare these measures in the future once AKASI is used more widely.
In contrast to the rest of the study population, one patient presented an increased standard AKASI of 34.8% and modified AKASI of 8.7%, respectively. There might be several reasons for this effect: The patient had a long follow-up period of 120 days.
Moreover, the patient developed AKs in a non-treated area, which was covered by the modified AKASI. Nevertheless, the AKASI of the scalp presented slightly higher at follow-up than at the baseline visit. Obviously, this patient appears refractory to PDT and/or shows high recurrence rates requiring continuous monitoring as well as more frequent AK treatments.
AKASI is a more differentiated assessment tool with comparable and graduated values. Assessment of treatment modalities which do not provide high PCCRs, as seen after PDT, benefit from a better graduated evaluation tool. Thus, AKASI can be used to precisely monitor therapy regimes.
The rationale of evaluating a complete lesion clearance in a chronic skin disease such as AKs must be questioned. To determine "time-to-relapse" is a better characteristic of therapeutic efficacy in a highly chronic disease such as AK. [19] Additionally, fielddirected measurements are needed to assess the efficacy of treatment approaches addressing field cancerisation. This study demonstrated AKASI and especially its thresholds such as AKASI 100, 75 and 50 to be a very feasible and easy-to use tool in daily clinical routine. These parameters could be also assigned as targets in clinical trials.
Interestingly, the difference of treatment outcome in treatment naïve patients and patients who has received at least one or more interventions prior to the recorded PDT was striking, although in a small study sample. Treatment naïve patients had significantly better outcomes than patients with a treatment history while there were no significant differences of AKASI at baseline in both groups. One hypothesis could be that patients presenting recurrent disease may be more refractory to treatment modalities as a whole. If this effect should be reproducible further studies with larger populations and other treatment approaches are mandatory.
Limitations of our study are the retrospective design and the small number of patients included. Moreover, the median AKASI at baseline visit of 3.8 ranges between mildto-moderate diseases when compared to the pivotal results. [9] Further studies should provide a broader range of disease severity in patients with AKs.
In conclusion, AKASI is a feasible tool to monitor treatment outcomes in patients with field cancerisation on the head. In analogy to other chronic skin disease such as psoriasis, AKASI 100, 75 and 50 worked out as easy-to apply and comparable assessment approach. Box-and-Whisker Plot concerning the differences in AKASI prior and after treatment.
Wilcoxon test shows highly significant differences (P < 0.0001) between AKASI at baseline visit (V0) and at the follow-up visit (V1) for both the standard AKASI (a) and the modified AKASI (b) (only treated areas were summed up).
Fig 2.
Differences of AKASI when compared baseline to follow-up visits.
Treatment naïve patients (n=13; 39.4%) illustrated as blue columns and patients who had received any intervention (n=20; 60.1%) are illustrated as red columns.
Differences between standard AKASI (a) and modified AKASI (only treated areas were summed up) (b). 14 (42.4%) patients when using the standard AKASI (a) and 16 (48.5%) patients using the modified AKASI (b) showed a complete clearance at follow-up visit.
Fig. 3.
Box-and-Whisker Plot concerning the AKASI changes between baseline and followup visit comparing treatment naïve patients and patients who had received any intervention. Mann-Whitney U test shows significant differences (P = 0.0302) between both groups.
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